Magnesium aspartate hydrochloride (DrugBank: Magnesium aspartate, Magnesium)
17 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
6 | パーキンソン病 | 0 |
11 | 重症筋無力症 | 0 |
13 | 多発性硬化症/視神経脊髄炎 | 0 |
46 | 悪性関節リウマチ | 0 |
51 | 全身性強皮症 | 0 |
64 | 血栓性血小板減少性紫斑病 | 0 |
70 | 広範脊柱管狭窄症 | 0 |
93 | 原発性胆汁性胆管炎[原発性胆汁性肝硬変 (~2017.3)] | 0 |
97 | 潰瘍性大腸炎 | 0 |
166 | 弾性線維性仮性黄色腫 | 0 |
225 | 先天性腎性尿崩症 | 0 |
235 | 副甲状腺機能低下症 | 0 |
284 | ダイアモンド・ブラックファン貧血 | 0 |
291 | ヒルシュスプルング病(全結腸型又は小腸型) | 0 |
296 | 胆道閉鎖症 | 0 |
297 | アラジール症候群 | 0 |
298 | 遺伝性膵炎 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2006-000087-83-GB (EUCTR) | 19/12/2008 | 04/12/2007 | EUROPAC2 trial to investigate the efficacy of ANTOX(vers) 1.2 and MGCT (magnesiocard) for the treatment of hereditary pancreatitis and idiopathic chronic pancreatitis. - EUROPAC2 | EUROPAC2 trial to investigate the efficacy of ANTOX(vers) 1.2 and MGCT (magnesiocard) for the treatment of hereditary pancreatitis and idiopathic chronic pancreatitis. - EUROPAC2 | Hereditary Pancreatitis and Idiopathic Chronic Pancreatitis MedDRA version: 13.1;Level: HLT;Classification code 10033646;Term: Acute and chronic pancreatitis;System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 13.1;Level: PT;Classification code 10056976;Term: Hereditary pancreatitis;System Organ Class: 10010331 - Congenital, familial and genetic disorders | Trade Name: Magnesiocard 2.5mmol Other descriptive name: MAGNESIUM ASPARTATE HYDROCHLORIDE Product Name: ANTOX (vers) 1.2 Product Code: ANTOX Other descriptive name: TOCOPHEROL INN or Proposed INN: ASCORBIC ACID Other descriptive name: SELENIUM INN or Proposed INN: METHIONINE | University of Liverpool | The Royal Liverpool and Broadgreen University Hospitals NHS Trust | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 240 | Phase 3 | United Kingdom |